Accessibility Menu
Bolt Biotherapeutics logo

Bolt Biotherapeutics(NASDAQ) BOLT

Market Cap$7.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-98%
1 Year-28%
1 Month+6%
$3.93
+1.55%
+0.06Today
After hours$4.03+$0.10 (+2.55%)
Bolt Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.992026-08-10
Bolt Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.25%USD 3.982026-08-03
1 month+5.56%USD 3.782026-07-10
3 month-16.53%USD 4.782026-05-12
Year to date-27.03%USD 5.472025-12-31
1 year-28.37%USD 5.572025-08-08
3 year-84.17%USD 25.202023-08-11
5 year-98.25%USD 228.202021-08-11
Since inception-99.37%USD 643.002021-02-05

Bolt Biotherapeutics Financials at a Glance

Market Cap

$7.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.50M

Net Income (TTM)

-$29.58M

EPS (TTM)

-$16.34

P/E Ratio

-0.24

Dividend

$0.00

Beta (Volatility)

0.82 (Low)

Price

$3.93

Volume

12,993.411

Open

$4.05

Previous Close

$3.99

Daily Range

$3.93 - $4.05

52-Week Range

$3.75 - $7.20

Estimated Earnings Date

Aug 13, 2026

BOLT News

Foolcom-Featured.png

Bolt Revenue Jumps 39 Percent in Q2

Motley Fool Markets TeamAug 14, 2025
Scientists unhappy

Why Bolt Biotherapeutics Stock Crashed Today

Keith SpeightsDec 6, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bolt Biotherapeutics

Bolt develops medicines that help the immune system fight cancer. Its treatments aim to make cancer cells easier for the body to find and destroy. These therapies are designed for people with hard-to-treat tumors.

Products and Services

  • Boltbody ISACs: Antibody-based drugs that help the immune system target cancer cells. (100% of revenue from collaborations)
  • BDC-4182: Early-stage drug for cancers with claudin 18.2 protein, in Phase 1 trials.
  • BDC-3042: Drug that changes immune cell behavior in tumors, in Phase 1 testing.
  • BDC-2034: Experimental therapy for several cancers, including colon and lung.
  • PD-L1 Program: Research for cancers that do not respond to current immune therapies.

Growth and Expansion

  • Discontinued BDC-1001 in May 2024 to focus on new candidates.
  • Launched BDC-4182 Phase 1 trial in April 2025.
  • Formed partnerships with Toray, Genmab, and Innovent to develop new drugs.
  • Opened Australian subsidiary in October 2024 for research and tax benefits.
  • Reduced workforce by approximately 50% in May 2024 as part of restructuring.

What Makes Bolt Stand Out

Bolt uses a unique technology that links antibodies to immune-activating molecules, aiming to reprogram the tumor environment. Its focus on myeloid biology sets it apart from companies using only traditional immune approaches. Strategic collaborations help Bolt access new technologies and expand its research pipeline.

Five Things You Need to Know

  • Collaboration revenue was $1.8 million in Q2 2025, up 41.5% year-on-year.
  • Net loss was $8.6 million in Q2 2025, improved 59.2% from Q2 2024.
  • Cash, cash equivalents, and investments totaled $48.5 million as of June 30, 2025.
  • Operating expenses fell to $11 million in Q2 2025, down 54% from Q2 2024.
  • All revenue comes from research partnerships, not product sales.

Bottom Line

Bolt has shifted focus to new drug candidates and partnerships after restructuring. The company remains early-stage, with all income from collaborations and ongoing research challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

23

CEO

William P. Quinn, MBA

Website

www.boltbio.com

Headquarters

Redwood City, CA 94063, US

BOLT Financials

Key Financial Metrics (TTM)

Gross Margin

96.88%

Operating Margin

-463.44%

Net Income Margin

-455.15%

Return on Equity

-100.90%

Return on Capital

-70.02%

Return on Assets

-61.59%

Earnings Yield

-4.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.92M

Volume

12.99K

Avg. Volume

24.29K

Financials (TTM)

Gross Profit

$6.30M

Operating Income

-$30.12M

EBITDA

-$28.49M

Operating Cash Flow

-$34.51M

Capital Expenditure

-$72.00K

Free Cash Flow

-$34.58M

Cash & ST Invst.

$22.89M

Total Debt

$22.31M

Bolt Biotherapeutics Performance Analysis

Bolt Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,729,000354.7%
20232023-12-31USD 7,876,00037.5%
20242024-12-31USD 7,690,000-2.4%
20252025-12-31USD 7,695,0000.1%
Bolt Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3047.6%
Q32025-09-3020.2%
Q42025-12-3115.3%
Q12026-03-31-99.0%
Bolt Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -47.16-10.5%
20232023-12-31USD -36.60-22.4%
20242024-12-31USD -33.06-9.7%
20252025-12-31USD -17.85-46.0%
Bolt Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1437.9%
Q32025-09-3016.6%
Q42025-12-31-3.2%
Q12026-03-31-0.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$26.00K

-97.9%

Gross Profit

-$177.00K

-114.5%

Gross Margin

-6.81%

N/A

Market Cap

$7.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$333.35K

N/A

Employees

23

N/A

Net Income

-$7.24M

+34.4%

EBITDA

-$7.04M

+33.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$22.89M

-41.1%

Total Debt

$22.31M

-9.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$19.35M

-13.3%

Short Term Debt

$2.96M

+23.2%

Return on Assets

-61.59%

N/A

Return on Invested Capital

-74.03%

N/A

Free Cash Flow

-$8.02M

+40.0%

Operating Cash Flow

-$8.02M

+40.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INABIN8bio, Inc.
$0.98-0.28%
EVGNEvogene Ltd.
$0.63+5.37%
IMNNImunon, Inc.
$1.63+1.24%
RNAZTransCode Therapeutics, Inc.
$3.88-2.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About BOLT

What is the current price of Bolt Biotherapeutics?

Bolt Biotherapeutics is trading at $3.99 per share.

What is the 52-week range for Bolt Biotherapeutics?

Over the past 52 weeks, Bolt Biotherapeutics has traded between $3.75 and $7.20.

How much debt does Bolt Biotherapeutics have?

As of the most recent reporting period, Bolt Biotherapeutics reported total debt of $22.31M.

How much cash does Bolt Biotherapeutics have on hand?

Bolt Biotherapeutics reported $11.81M in cash and cash equivalents in its most recent financial results.

What is Bolt Biotherapeutics’s dividend yield?

Bolt Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services